Literature DB >> 11153137

Aspirin--the first hundred years.

P Stanley1, R Hegedus.   

Abstract

'Take two aspirin and call me in the morning', may be an old cliché deriding the medical profession, but the story of the first 100 years of aspirin suggests that this drug may be of benefit for a far greater range of ailments than those who synthesised it 100 years ago could have imagined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11153137

Source DB:  PubMed          Journal:  Biologist (London)        ISSN: 0006-3347


  4 in total

1.  Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.

Authors:  Liqun Huang; Gerardo G Mackenzie; Yu Sun; Nengtai Ouyang; Gang Xie; Kvetoslava Vrankova; Despina Komninou; Basil Rigas
Journal:  Cancer Res       Date:  2011-10-24       Impact factor: 12.701

2.  Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice.

Authors:  George Mattheolabakis; Ioannis Papayannis; Jennifer Yang; Brandon M Vaeth; Ruixue Wang; Jela Bandovic; Nengtai Ouyang; Basil Rigas; Gerardo G Mackenzie
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-02

3.  Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect.

Authors:  Liqun Huang; Chi C Wong; Ka W Cheng; Basil Rigas
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

4.  Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress.

Authors:  Liqun Huang; Chi C Wong; Gerardo G Mackenzie; Yu Sun; Ka Wing Cheng; Kvetoslava Vrankova; Ninche Alston; Nengtai Ouyang; Basil Rigas
Journal:  BMC Cancer       Date:  2014-02-28       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.